Jillian Burk, MPH

Harvard Pilgrim Health Care Institute

Poster(s):

• (A-350) Baseline Characteristics of Patients Included in a Post-Approval Safety Study of Pfizer-BioNTech Monovalent COVID-19 Vaccine in the United States: Results From an Interim Analysis
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (C-247) Cannabis-Related Healthcare Encounters among Commercially Insured Adults Aged 18-64 Years Contributing Data to the US Food And Drug Administration’s Sentinel, 2017-2022
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET

• (A-333) Incidence Rates of Safety Events of Interest in a Post-Approval Study of Pfizer-BioNTech Original Monovalent COVID-19 Vaccine in the United States: Primary Series Analysis
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (A-334) Incidence rates of safety outcomes in a post-approval study of the Pfizer-BioNTech monovalent COVID-19 vaccine in the United States, booster dose analysis
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (A-316) Risk of Diabetic Ketoacidosis Across Stages of Chronic Kidney Disease in Patients with Type 1 Diabetes in the U.S. Food and Drug Administration’s Sentinel System
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET